IMMUNE MODULATORY THERAPIES, LLC

Biotech · Private

ExoBlock, a synthetic compound that binds phosphatidylserine on tumor-derived exosomes to block immune suppression and enhance T cell killing of cancer cells

Grants
$574K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Reversing/Blocking T cell suppression by extracellular vesicles as cancer therapy$280,928
Federal grantDepartment of Health and Human Services · Phase I · Novel Drug for Cancer Immunotherapy that Targets Phosphatidylserine$293,178
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1280ASYMMETREX, LLC——
1281FPRT BIO, INC.——
1282ADVANCED VIROLOGY INC.——
1283IMMUNE MODULATORY THERAPIES, LLC——
1284XLOCK BIOSCIENCES, LLC——
1285GENETIC INTELLIGENCE——
1286BINARY GENOMICS, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 3
  • Phosphatidylserine Binding Molecules Block Immune Suppression Of Tumor Associated Exosomesapplication
  • Phosphatidylserine Binding Molecules Block Immune Suppression Of Tumor Associated Exosomesapplication
  • Phosphatidylserine Binding Molecules Block Immune Suppression Of Tumor Associated Exosomesapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.